• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects.

作者信息

Hall K W, Nightingale C H, Gibaldi M, Nelson E, Bates T R, DiSanto A R

出版信息

J Clin Pharmacol. 1982 Jul;22(7):321-5. doi: 10.1002/j.1552-4604.1982.tb02682.x.

DOI:10.1002/j.1552-4604.1982.tb02682.x
PMID:7107981
Abstract

The objective of this study was to compare the pharmacokinetic behavior of erythromycin in normal volunteers with that in subjects with alcoholic liver disease. Six normal volunteers received 500 mg erythromycin as an intravenous infusion or as two 250-mg enteric-coated tablets in a crossover fashion. The pharmacokinetics of erythromycin after intravenous administration was best described as a two-compartment model. The elimination half-life was 1.6 +/- 0.7 hours (mean +/- S.D.) after the intravenous dose and 2.0 +/- 0.7 hours after the oral dose. In patients with alcoholic liver disease the elimination half-life after oral administration of two 250-mg enteric-coated tablets was 3.2 +/- 0.5 hours, significantly different from that in normal subjects, probably due to impaired metabolism. The difference in half-life does not require dosage adjustment in this patient population. The systemic availability of erythromycin was 33.5 per cent (range 10.5 to 79.3 per cent).

摘要

相似文献

1
Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects.
J Clin Pharmacol. 1982 Jul;22(7):321-5. doi: 10.1002/j.1552-4604.1982.tb02682.x.
2
Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients.
Clin Pharmacol Ther. 1990 Mar;47(3):354-9. doi: 10.1038/clpt.1990.39.
3
Bioinequivalence of erythromycin ethylsuccinate and enteric-coated erythromycin pellets following multiple oral doses.
J Clin Pharmacol. 1985 Jan-Feb;25(1):36-42. doi: 10.1002/j.1552-4604.1985.tb02798.x.
4
Flumazenil disposition and elimination in cirrhosis.
Clin Pharmacol Ther. 1989 Sep;46(3):317-23. doi: 10.1038/clpt.1989.145.
5
Absorption of erythromycin stearate and enteric-coated erythromycin base after a single oral dose immediately before breakfast.早餐前单次口服硬脂酸红霉素和肠溶红霉素碱后的吸收情况。
Infection. 1984 Sep-Oct;12(5):345-8. doi: 10.1007/BF01651150.
6
Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole.肝硬化对氯美噻唑药代动力学的影响。
Br Med J. 1978 Sep 23;2(6141):861-3. doi: 10.1136/bmj.2.6141.861.
7
Pharmacokinetics and protein binding of cefpiramide in patients with alcoholic cirrhosis.头孢匹胺在酒精性肝硬化患者中的药代动力学及蛋白结合率
Clin Pharmacol Ther. 1991 Mar;49(3):263-9. doi: 10.1038/clpt.1991.27.
8
Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
Postgrad Med J. 1986;62 Suppl 2:29-37.
9
Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.CYP3A4抑制剂红霉素对肝功能正常和受损受试者中利多卡因及其药理活性代谢产物药代动力学的影响。
Br J Clin Pharmacol. 2003 Jan;55(1):86-93. doi: 10.1046/j.1365-2125.2003.01718.x.
10
Pharmacokinetics of single-dose erythromycin in normal and alcoholic liver disease subjects.单剂量红霉素在正常人和酒精性肝病患者中的药代动力学。
Antimicrob Agents Chemother. 1982 Jan;21(1):135-40. doi: 10.1128/AAC.21.1.135.

引用本文的文献

1
Drug interactions with zidovudine phosphorylation in vitro.齐多夫定磷酸化的体外药物相互作用。
Antimicrob Agents Chemother. 1995 Jun;39(6):1376-8. doi: 10.1128/AAC.39.6.1376.
2
Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.严重肝硬化患者中红霉素的药代动力学。血清结合力降低和肝脏代谢能力受损的各自影响。
Br J Clin Pharmacol. 1987 Jun;23(6):753-7. doi: 10.1111/j.1365-2125.1987.tb03111.x.
3
Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography.
通过高压液相色谱法测定依托红霉素相对于琥乙红霉素的药代动力学优势。
Antimicrob Agents Chemother. 1988 Apr;32(4):561-5. doi: 10.1128/AAC.32.4.561.
4
Guide to drug dosage in hepatic disease.肝病用药剂量指南。
Clin Pharmacokinet. 1988 Dec;15(6):396-420. doi: 10.2165/00003088-198815060-00004.
5
Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).大环内酯类抗生素的临床药代动力学特性。年龄及各种病理生理状态的影响(第二部分)
Clin Pharmacokinet. 1989 May;16(5):261-82. doi: 10.2165/00003088-198916050-00001.
6
Bioavailability of erythromycin acistrate from hard gelatin capsules containing sodium bicarbonate.含碳酸氢钠的硬明胶胶囊中阿西环酯红霉素的生物利用度。
Pharm Res. 1991 Aug;8(8):1056-8. doi: 10.1023/a:1015869410783.